Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
Tectonic Therapeutic, Inc. (TECX)
Company Research
Source: GlobeNewswire
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), supporting endpoints and patient population in ongoing APEX Phase 2 clinical trialInterim analysis demonstrated that TX45 achieved 17.9% reduction in Pulmonary Capillary Wedge Pressure (“PCWP”) in the total study population of PH-HFpEF and 30% reduction in Pulmonary Vascular Resistance (“PVR”) in Combined pre- and post-capillary PH (“CpcPH”), a subpopulation with more severe diseaseTX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events, significant hypotension, or immune related reactionsCompany to host conferen
Read more
Impact Snapshot
Event Time:
TECX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TECX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TECX alerts
High impacting Tectonic Therapeutic, Inc. news events
Weekly update
A roundup of the hottest topics
TECX
News
- Tectonic Therapeutic (NASDAQ: TECX) had its price target lowered by analysts at Wells Fargo & Company from $112.00 to $101.00. They now have an "overweight" rating on the stock.MarketBeat
- Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsGlobeNewswire
- Tectonic Therapeutic to Participate in March Investor ConferencesGlobeNewswire
- Tectonic Announces $185 Million Private Placement [Yahoo! Finance]Yahoo! Finance
- Tectonic Announces $185 Million Private PlacementGlobeNewswire
TECX
Earnings
- 3/20/25 - Beat
TECX
Sec Filings
- 4/4/25 - Form EFFECT
- 4/3/25 - Form EFFECT
- 3/27/25 - Form POS
- TECX's page on the SEC website